Overview

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, Phase 1 / 2 clinical study for patients with advanced solid tumors. The study consists of 2 treatment arms - a monotherapy arm and a combination arm. The monotherapy arm has 1 part: Dose Escalation (Part A) The combination arm has Dose Escalation (Part B) only.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Boston Biomedical, Inc
Sumitomo Dainippon Pharma Oncology, Inc
Collaborator:
Syneos Health
Treatments:
Pembrolizumab